| DON'T BUY | 15.950 | Ross Healy | Had an earnings disappointment. FMV trend is sharply down. When factoring in analysts forecasts, the FMV is about $12.30. | 2007-03-07 | |
| BUY on WEAKNESS | 23.170 | Brian Acker, CA | Will have to go to $20.50 before it has a bounce. Has a model price of $31.95 which is a 37/38% differential. | 2005-09-21 | |
| BUY | 26.210 | Gavin Graham | In a lawsuit with Johnson and Johnson (JNJ-N), so a lot depends on who wins the case. Their product works better than JNJ and he continues to like it. | 2005-09-06 | |
| BUY | 27.480 | Gavin Graham | Things look good for them. Won a patent case against Johnson & Johnson (JNJ-N). | 2005-07-13 | |
| WEAK BUY | 30.600 | Brian Acker, CA | It's close to a buy. Model price is $32.09 which is a 5% differential. | 2005-05-24 | |
| TOP PICK | 30.000 | Kevin Vandermeer, B.Comm, CFA | "We really like Boston [Scientific]" Thinks they have a better product then the competitor. Had a series of recalls, but have been able to gain back the marketshare. But the stock didn't recover as well. So is now undervalued. | 2005-03-11 | |
| DON'T BUY | 34.810 | Ron Meisels | Long term chart shows that it made a base, had a fantastic rise to $45 in 2002/2003, very little top formation and now we are in a downtrend. Stock has now fallen below its 200 day moving average. | 2005-02-01 | |
| BUY | 31.880 | David Baskin | A good company. Their coated stents is a terrific product. Up against Johnson & Johnson in the stent business, but they are holding their own. A good buy at this price. | 2005-01-25 | |
| WEAK BUY | 32.370 | Brad Willock | Stock has dropped because of the recall of their stent. Price is reasonably attractive. | 2004-08-13 | |
| TOP PICK | 44.300 | Mary Farrell | A company that focuses on earnings. A tremendous new product that should give a nice boost to their income. | 2004-05-28 | |
| DON'T BUY | 41.500 | Matt Barasch | Its drug coated stent is driving the price up, but other competitors are lurking on the horizon. Not cheap. | 2004-02-19 | |
| TOP PICK | 48.000 | David Burrows | Likes this sector. Strong and persistant growth. Revenue and earnings growth has been very persistant. Good products. Buy on pull backs. | 2003-05-13 | |
Experts that have talked about Boston Scientific Corp
Rss Top Picks Feed
